Novo Nordisk Licenses Omeros' Rare Disease Drug For $2.1B
Denmark's Novo Nordisk SA said Wednesday that it will license an antibody from U.S. biopharma Omeros Corp. for up to $2.1 billion in order to expand its portfolio of therapies for...To view the full article, register now.
Already a subscriber? Click here to view full article